Graft-versus-host disease free, relapse-free survival after allogeneic stem cell transplantation for myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders with dismal prognosis,1 especially in patients with higher-risk MDS or those with lower-risk MDS having poor prognostic features.2 Despite recent advances in knowledges of genetic and molecular pathogenesis,3 therapies for MDS currently remain to use nonspecific approaches with unsatisfactory results. Among variable therapeutic options, allogeneic hematopoietic stem cell transplantation (HSCT) is peculiar in that it is the only considered option to cure MDS.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Sung-Soo Park, Young-Woo Jeon, Gi June Min, Silvia Park, Seung-Ah Yahng, Jae-Ho Yoon, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Yoo-Jin Kim Source Type: research
More News: Biology | Genetics | Molecular Biology | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplants